Paris, France, November 18, 2026
Sanofi has announced that the U.S. Food and Drug Administration (FDA) has approved Infilbray (venglustat) as the first medicine specifically indicated to treat the neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg. The once-daily oral medicine is a novel glucosylceramide synthase inhibitor (GCSi) designed to act across the blood-brain barrier and address the accumulation of harmful glycosphingolipids associated with neurological damage. The approval represents a significant development for people living with this rare inherited disorder, in which available enzyme replacement therapies have helped manage systemic symptoms but have not adequately addressed the neurological complications. The FDA decision was supported by positive results from the Phase 3 LEAP2MONO clinical study, which demonstrated statistically significant improvements in neurological measures compared with imiglucerase enzyme replacement therapy. The approval introduces a new treatment approach for patients experiencing cognitive difficulties and problems with coordination and balance associated with GD3.
Infilbray Targets Neurological Manifestations of Gaucher Disease
Type 3 Gaucher disease is a rare, chronic neuronopathic form of Gaucher disease caused by inherited deficiency of the enzyme glucocerebrosidase, also known as acid beta-glucosidase. This deficiency results in the accumulation of glycosphingolipids, particularly glucosylceramide and related molecules, in various tissues. While Gaucher disease can affect the spleen, liver, bone marrow and other organs, Type 3 disease also involves the central nervous system (CNS). Patients may experience progressive neurological manifestations, including cognitive impairment, difficulty with coordination and balance, and other complications that can affect daily functioning. Existing enzyme replacement therapies can help control systemic manifestations, such as enlarged organs and blood-related abnormalities, but they do not effectively cross the blood-brain barrier to treat neurological disease. Infilbray is designed to address this treatment gap through an oral mechanism that inhibits glucosylceramide synthase, an enzyme involved in the production of glycosphingolipids. By reducing the formation of these molecules, the medicine aims to limit their abnormal accumulation and associated disease processes within the body and brain.
Phase 3 LEAP2MONO Trial Demonstrated Neurological Benefits
The FDA approval was based on findings from the Phase 3 LEAP2MONO study, a double-blind, double-dummy, active-comparator clinical trial evaluating once-daily oral Infilbray against intravenous imiglucerase administered every two weeks. The study enrolled 43 adults and pediatric patients aged 12 years and older with neurological manifestations of GD3. Participants had previously received enzyme replacement therapy for at least three years and achieved treatment goals for their systemic disease manifestations. The primary endpoint assessed changes from baseline to Week 52 using two neurological measures: the four-item modified Scale for the Assessment and Rating of Ataxia (mSARA), which evaluates motor function, and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score, which assesses cognitive function. Infilbray demonstrated statistically significant superiority over imiglucerase in the combined global assessment of these neurological endpoints, with a p-value of 0.0137. The results indicated improvements in selected neurological manifestations associated with cognitive deficits and difficulties in coordination and balance. The trial also evaluated systemic disease measures, including spleen and liver volume, hemoglobin levels and platelet counts, alongside biomarkers in plasma and cerebrospinal fluid. The open-label extension of the study remains ongoing, with further findings expected to provide additional information about longer-term treatment outcomes.
Safety Profile and Global Regulatory Development
In the primary analysis period, the most frequently reported adverse reactions among patients receiving Infilbray included diarrhea, splenomegaly and nausea, each reported in 14% of participants. Depression, gastroenteritis and vomiting were also reported. The FDA-approved medicine carries important warnings and precautions relating to suicidal ideation and behavior, lens opacification in pediatric patients, and embryo-fetal toxicity. Healthcare professionals must consider these risks when evaluating treatment suitability and monitoring patients. Infilbray previously received several U.S. regulatory designations, including Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations. The medicine is also under regulatory review for GD3 in the European Union, Japan and other jurisdictions. Sanofi plans to pursue additional global regulatory submissions during 2026 and 2027.
The U.S. approval marks an important advancement in the treatment of a rare neurological disorder with substantial unmet medical needs. By introducing an oral therapy designed to reach the central nervous system, Sanofi aims to address neurological complications that have remained difficult to manage with existing treatments. Continued monitoring, additional clinical data and regulatory decisions in other countries will help establish the medicine’s role in the broader management of Type 3 Gaucher disease.
Source: Sanofi press release



